婴儿血管瘤的治疗误区

2015-03-29 cmt cmt

1误区:婴幼儿血管瘤治疗效果单纯以瘤体缩小程度为评价指标就目前的技术水平而言,婴幼儿血管瘤治疗的目标应该是最终的治疗效果要优于自然消退。目前大部分血管瘤的治疗方案都是以抑制血管瘤增生或者促进其消退为主要目标。过份强调瘤体的缩小反而增加了导致严重并发症和医源性损伤的风险。2误区:激光治疗是婴幼儿血管瘤治疗的首选方法激光治疗血管瘤和血管畸形疾病要特别注意适应症的掌握和激光类型的选择。激光治疗的前提是不

1误区:婴幼儿血管瘤治疗效果单纯以瘤体缩小程度为评价指标

就目前的技术水平而言,婴幼儿血管瘤治疗的目标应该是最终的治疗效果要优于自然消退。目前大部分血管瘤的治疗方案都是以抑制血管瘤增生或者促进其消退为主要目标。过份强调瘤体的缩小反而增加了导致严重并发症和医源性损伤的风险。

2误区:激光治疗是婴幼儿血管瘤治疗的首选方法

激光治疗血管瘤和血管畸形疾病要特别注意适应症的掌握和激光类型的选择。激光治疗的前提是不能给未来消退后的皮肤增加一点疤痕,记住激光对接近实体的婴幼儿血管瘤的治疗并非高度特异的。

3.误区:口服激素容易出现并发症,所以不能应用。

大量实际案例证明口服激素对婴幼儿血管瘤中的治疗是有效,但是必须严格掌握口服激素治疗的适应症,防止激素的滥用。对于体积大、部位多或特殊部位的血管瘤,口服激素不仅适用,而且从长期随访来看,是安全的。

4.误区:所有的血管瘤都是会消退所以不需要治疗。

对于明确在增生的血管瘤若不给予治疗,最终过度的持续生成不仅大大延长了消退的年数,更增加了永久畸形的可能性。另外鼻尖,上唇等特殊部位的血管瘤消退时间常较长,有的学者从心理角度出发,认为外科手术等早期积极治疗都应该在考虑之列。

5误区:冷冻方法是血管瘤治疗的常用方法。

冷冻方法治疗血管瘤结果常常留下明显的瘢痕,是不建议的。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=42155, encodeId=9b1742155ae, content=激光治疗首选?, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2d1658827, createdName=桥断梅边, createdTime=Sun Nov 01 17:29:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071118, encodeId=c2d720e111852, content=<a href='/topic/show?id=4be145091f1' target=_blank style='color:#2F92EE;'>#婴儿血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45091, encryptionId=4be145091f1, topicName=婴儿血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Wed Jun 24 07:03:00 CST 2015, time=2015-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308752, encodeId=85111308e5226, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Mar 31 11:03:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348245, encodeId=ebef134824592, content=<a href='/topic/show?id=1eaf89e26d3' target=_blank style='color:#2F92EE;'>#血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89726, encryptionId=1eaf89e26d3, topicName=血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Mar 31 11:03:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19055, encodeId=bbe819055c1, content=beta阻滞剂应该首选, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=101.231.243.**, createdTime=Mon Mar 30 14:53:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
    2015-11-01 桥断梅边

    激光治疗首选?

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=42155, encodeId=9b1742155ae, content=激光治疗首选?, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2d1658827, createdName=桥断梅边, createdTime=Sun Nov 01 17:29:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071118, encodeId=c2d720e111852, content=<a href='/topic/show?id=4be145091f1' target=_blank style='color:#2F92EE;'>#婴儿血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45091, encryptionId=4be145091f1, topicName=婴儿血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Wed Jun 24 07:03:00 CST 2015, time=2015-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308752, encodeId=85111308e5226, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Mar 31 11:03:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348245, encodeId=ebef134824592, content=<a href='/topic/show?id=1eaf89e26d3' target=_blank style='color:#2F92EE;'>#血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89726, encryptionId=1eaf89e26d3, topicName=血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Mar 31 11:03:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19055, encodeId=bbe819055c1, content=beta阻滞剂应该首选, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=101.231.243.**, createdTime=Mon Mar 30 14:53:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=42155, encodeId=9b1742155ae, content=激光治疗首选?, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2d1658827, createdName=桥断梅边, createdTime=Sun Nov 01 17:29:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071118, encodeId=c2d720e111852, content=<a href='/topic/show?id=4be145091f1' target=_blank style='color:#2F92EE;'>#婴儿血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45091, encryptionId=4be145091f1, topicName=婴儿血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Wed Jun 24 07:03:00 CST 2015, time=2015-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308752, encodeId=85111308e5226, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Mar 31 11:03:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348245, encodeId=ebef134824592, content=<a href='/topic/show?id=1eaf89e26d3' target=_blank style='color:#2F92EE;'>#血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89726, encryptionId=1eaf89e26d3, topicName=血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Mar 31 11:03:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19055, encodeId=bbe819055c1, content=beta阻滞剂应该首选, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=101.231.243.**, createdTime=Mon Mar 30 14:53:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=42155, encodeId=9b1742155ae, content=激光治疗首选?, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2d1658827, createdName=桥断梅边, createdTime=Sun Nov 01 17:29:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071118, encodeId=c2d720e111852, content=<a href='/topic/show?id=4be145091f1' target=_blank style='color:#2F92EE;'>#婴儿血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45091, encryptionId=4be145091f1, topicName=婴儿血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Wed Jun 24 07:03:00 CST 2015, time=2015-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308752, encodeId=85111308e5226, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Mar 31 11:03:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348245, encodeId=ebef134824592, content=<a href='/topic/show?id=1eaf89e26d3' target=_blank style='color:#2F92EE;'>#血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89726, encryptionId=1eaf89e26d3, topicName=血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Mar 31 11:03:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19055, encodeId=bbe819055c1, content=beta阻滞剂应该首选, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=101.231.243.**, createdTime=Mon Mar 30 14:53:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=42155, encodeId=9b1742155ae, content=激光治疗首选?, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2d1658827, createdName=桥断梅边, createdTime=Sun Nov 01 17:29:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071118, encodeId=c2d720e111852, content=<a href='/topic/show?id=4be145091f1' target=_blank style='color:#2F92EE;'>#婴儿血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45091, encryptionId=4be145091f1, topicName=婴儿血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Wed Jun 24 07:03:00 CST 2015, time=2015-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308752, encodeId=85111308e5226, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Mar 31 11:03:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348245, encodeId=ebef134824592, content=<a href='/topic/show?id=1eaf89e26d3' target=_blank style='color:#2F92EE;'>#血管瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89726, encryptionId=1eaf89e26d3, topicName=血管瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Mar 31 11:03:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19055, encodeId=bbe819055c1, content=beta阻滞剂应该首选, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=101.231.243.**, createdTime=Mon Mar 30 14:53:00 CST 2015, time=2015-03-30, status=1, ipAttribution=)]
    2015-03-30 101.231.243.**

    beta阻滞剂应该首选

    0

相关资讯

NEJM:普萘洛尔治疗婴儿血管瘤的用法

目前口服普萘洛尔已经用于治疗婴儿血管瘤,其相关临床数据来自随机对照试验,但是具体使用方法却不明确。因此C. Léauté-Labrèze等人进行了一项多中心、随机、双盲、适配的2-3期试验,以探究对1-5个月大患有增殖性婴儿血管瘤、需要系统治疗的婴儿的儿科专门的普萘洛尔给药方案,并且评估其有效性和安全性。最新研究成果发表在2015-02-19 NEJM。该研究将纳入人群随机分为